Eli Lilly and Co. (NYSE:LLY) is phasing out select insulin products across parts of Europe for commercial reasons, with regulators emphasizing that the move is not linked to safety or quality concerns.

The withdrawals, which vary by country, are expected to be completed before the second quarter of 2027.

Select Insulin Products To Be Withdrawn By 2027

The company confirmed it will discontinue certain insulin presentations containing human insulin, insulin lispro, and insulin glargine across multiple EU and EEA markets.

The specific products impacted, along with the timing of their removal, differ by country.

Separately, Humalog Mix25, a formulation combining insulin lispro and insulin lispro protamine, has already been discontinued in all EU and EEA countries where it was ...